Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144


Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.

Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriëns JH, Venter F, Lundgren J, Phillips A.

AIDS. 2014 Jan;28 Suppl 1:S15-23. doi: 10.1097/QAD.0000000000000082.


HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.


Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.


The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models.

Pretorius C, Menzies NA, Chindelevitch L, Cohen T, Cori A, Eaton JW, Fraser C, Gopalappa C, Hallett TB, Salomon JA, Stover J, White RG, Dodd PJ.

AIDS. 2014 Jan;28 Suppl 1:S25-34. doi: 10.1097/QAD.0000000000000085.


Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.

Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy N, Morris L, Walker BD, Goulder P.

AIDS. 2008 Jul 11;22(11):1333-43. doi: 10.1097/QAD.0b013e32830437df.


Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.


Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.

Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, Imrie J, Bärnighausen T, Rekacewicz C, Bazin B, Newell ML, Dabis F; ANRS 12249 TasP Study Group.

Trials. 2013 Jul 23;14:230. doi: 10.1186/1745-6215-14-230.


High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.

Fofana DB, Soulié C, Baldé A, Lambert-Niclot S, Sylla M, Ait-Arkoub Z, Diallo F, Sangaré B, Cissé M, Maïga IA, Fourati S, Koita O, Calvez V, Marcelin AG, Maïga AI.

J Antimicrob Chemother. 2014 Sep;69(9):2531-5. doi: 10.1093/jac/dku153. Epub 2014 May 22.


Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.

Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW.

J Infect Dis. 2013 Jul 15;208(2):224-34. doi: 10.1093/infdis/jit150. Epub 2013 Apr 9.


[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].

Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.

Dtsch Med Wochenschr. 2007 May 4;132(18):977-82. German.


High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M.

J Int AIDS Soc. 2011 Jun 10;14:30. doi: 10.1186/1758-2652-14-30.


Cascade of HIV care and population viral suppression in a high-burden region of Kenya.

Maman D, Zeh C, Mukui I, Kirubi B, Masson S, Opolo V, Szumilin E, Riche B, Etard JF.

AIDS. 2015 Jul 31;29(12):1557-65. doi: 10.1097/QAD.0000000000000741.


Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.

Ying R, Sharma M, Celum C, Baeten JM, van Rooyen H, Hughes JP, Garnett G, Barnabas RV.

Lancet HIV. 2016 Jun;3(6):e275-82. doi: 10.1016/S2352-3018(16)30009-1. Epub 2016 May 11.


How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?

Scott Braithwaite R, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, Keebler D, Hallett T.

AIDS. 2014 Jan;28 Suppl 1:S73-83. doi: 10.1097/QAD.0000000000000110.


Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.

Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D.

J Antimicrob Chemother. 2015;70(6):1881-4. doi: 10.1093/jac/dkv030. Epub 2015 Feb 18.


Effective treatment of patients in a deep salvage situation with "non-active HAART": experiences with the expert advice system RADATA.

Lorenzen T, Walther I, Stoehr A, Salzberger B, Plettenberg A; Radata Study Group.

Infection. 2009 Dec;37(6):528-33. doi: 10.1007/s15010-009-9022-6. Epub 2009 Oct 13.


HIV type 1 virological response and prevalence of HIV type 1 drug resistance among patients receiving antiretroviral therapy, Shandong, China.

Zhang J, Kang D, Lin B, Sun X, Fu J, Bi Z, Nkengasong JN, Yang C.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1658-65. doi: 10.1089/AID.2012.0019. Epub 2012 Jun 11.


Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level.

Palombi L, Bernava GM, Nucita A, Giglio P, Liotta G, Nielsen-Saines K, Orlando S, Mancinelli S, Buonomo E, Scarcella P, Altan AM, Guidotti G, Ceffa S, Haswell J, Zimba I, Magid NA, Marazzi MC.

Clin Infect Dis. 2012 Jul;55(2):268-75. doi: 10.1093/cid/cis380. Epub 2012 Apr 5.


It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Zyl GU, Rabie H, Nuttall JJ, Cotton MF.

J Int AIDS Soc. 2011 Nov 15;14:55. doi: 10.1186/1758-2652-14-55.


Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, Laborde-Balen G, Aghokeng A, Suzan-Monti M, Delaporte E, Spire B, Carrieri MP, Laurent C; Stratall ANRS 12110/ESTHER Study Group.

HIV Med. 2014 Sep;15(8):478-87. doi: 10.1111/hiv.12140. Epub 2014 Mar 3.

Supplemental Content

Support Center